drugset / Trial / NCT04862780
(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anticancer activity of BLU-945, a selective EGFR inhibitor, as monotherapy or in combination with osimertinib.
Timeline
- Start
- 2021-06-29
- Primary completion
- 2024-10-07
- Completion
- 2024-10-07
Outcome
Outcome not reported
Stopped (Business): “Sponsor decision, not related to safety concerns”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BLU-945 | Unknown | — | Oral |
| Subject | Osimertinib | Small molecule | 80 mg | Oral |